APLS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 2, 2023 in the Class Action Filed on Behalf of Apellis Pharmaceuticals, Inc. Shareholders
NEW YORK, Aug. 8, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) alleging that the Company violated federal securities laws.
Class Period: January 28, 2021 to July 28, 2023
Lead Plaintiff Deadline: October 2, 2023
No obligation or cost to you.
Learn more about your recoverable losses in APLS:
https://www.kleinstocklaw.com/pslra-1/apellis-lawsuit-loss-submission-form?id=43099&from=4
Apellis Pharmaceuticals, Inc. NEWS - APLS NEWS
CLASS ACTION CASE DETAILS: The filed complaint alleges that Apellis Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the design of SYFOVRE's clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections; (2) as a result, the commercial adoption of SYFOVRE was subject to significant, unknown risk factors; and (3) therefore, defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.
WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Apellis you have until October 2, 2023 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you purchased Apellis securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.
HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the APLS lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link: https://www.kleinstocklaw.com/pslra-1/apellis-lawsuit-loss-submission-form?id=43099&from=4.
ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
535 Fifth Avenue
4th Floor
New York City, NY 10017
jk@kleinstocklaw.com
Telephone: (212) 616-4899
www.kleinstocklaw.com
SOURCE The Klein Law Firm
Ausgewählte Hebelprodukte auf Apellis Pharmaceuticals
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Apellis Pharmaceuticals
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Apellis Pharmaceuticals Aktie News
Apellis Pharmaceuticals Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Apellis Pharmaceuticals nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 01.08.19 | Apellis Pharmaceuticals Overweight | Cantor Fitzgerald | |
| 30.07.18 | Apellis Pharmaceuticals Buy | B. Riley FBR | |
| 24.05.18 | Apellis Pharmaceuticals Overweight | Cantor Fitzgerald | |
| 12.04.18 | Apellis Pharmaceuticals Neutral | B. Riley FBR, Inc. | |
| 08.02.18 | Apellis Pharmaceuticals Buy | B. Riley FBR, Inc. |